Heartflow, Inc. HTFL 深 滬
等待開盤 10-28 09:30:00 美东时间
38.34
+0.470
+1.24%
華盛通- 最 高40.24
- 今 開38.63
- 成交量 33.12万股
- 最 低 37.06
- 昨 收 37.87
- 總市值 31.12亿
- 52周最高 41.2231
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 26.56
- 委 比 -95.69%
- 總股本 8116.84万
- 歷史最高 41.2231
- 量 比 0.98
- 振 幅 8.40%
- 歷史最低 26.56
- 每 手 1
- 風險率 3.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025
<p>Heartflow, Inc. announced it will release its third-quarter 2025 financial results after market close on November 12, 2025. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET that day, with registration available via the provided link. Heartflow's AI-driven technology for coronary artery disease has redefined clinical care, supported by extensive research and compliance with global security standards. For more information, visit the...
10-23 20:05
New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning
Heartflow introduced Heartflow PCI Navigator, an AI-driven PCI planning tool offering patient-specific 3D models to optimize stent placement. The tool integrates anatomy, plaque composition, and lesion-specific physiology, streamlining cath lab decision-making. At TCT 2025, Heartflow will showcase PCI Navigator and present the PLAN CALCIUM study, demonstrating AI-powered plaque analysis in lesion preparation. Additionally, the NAVIGATE-PCI regist...
10-22 12:00
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Heartflow Receives FDA 510(k) Clearance For Its Next Gen Heartflow Plaque Analysis Algorithm
MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug
09-23 04:08
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $39
Canaccord Genuity analyst William Plovanic maintains HeartFlow (NASDAQ:HTFL) with a Buy and raises the price target from $35 to $39.
09-22 20:09
Piper Sandler Initiates Coverage On HeartFlow with Overweight Rating, Announces Price Target of $38
Piper Sandler analyst Matt OBrien initiates coverage on HeartFlow (NASDAQ:HTFL) with a Overweight rating and announces Price Target of $38.
09-02 18:16
Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Heartflow, Inc., a leader in AI technology for coronary artery disease, announced that its management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. A live and archived version will be available on Heartflow's website. Heartflow's AI-driven platform, Heartflow One, offers non-invasive coronary care solutions, supported by clinical guidelines and peer-reviewed research, hel...
08-27 20:24
HeartFlow, Inc. Terminates Credit Agreement with Hayfin
HeartFlow, Inc. ( ($HTFL) ) has issued an update. On August 22, 2025, HeartFlow...
08-26 04:42
一脉阳光早盘拉升逾8% 海内外医学影像赛道火热
一脉阳光（02522）早盘拉升逾8%，截至发稿，股价上涨7.81%，报18.77港元，成交额4.27亿港元。 美国东部时间周三，心脏AI诊断公司Hea...
08-15 10:20
港股异动 | 一脉阳光(02522)早盘拉升逾8% 海内外医学影像赛道火热 公司AI战略商业化基础奠定完成
一脉阳光(02522)早盘拉升逾8%，截至发稿，涨7.64%，报18.74港元，成交额2.16亿港元。 消息面上，美国东部时间周三，心脏AI诊断公司Heart...
08-15 09:43
